For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Study achieves primary endpoint of radiographic progression-free survival
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
If implemented across the world, it has the capability to save over 100,000 lives annually
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Subscribe To Our Newsletter & Stay Updated
